Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 6Lymphoid 2Gastrointestinal 2Other neoplasm 1Other hematologic neoplasm 1Myeloid 1CNS 1

Conditions

Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 297Fluorouracil 272Bevacizumab 235Gemcitabine 234Leucovorin 212Capecitabine 204pembrolizumab 200Nivolumab 157Irinotecan 156Cisplatin 148Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73Folfox protocol 68lenvatinib 67Carboplatin 65regorafenib 60Blood Specimen Collection 60trifluridine tipiracil drug combination 52Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thalidomide × Gastrointestinal × 1 year × Clear all
NCT07321613 2026-01-07

Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

Shanghai Zhongshan Hospital

Completed
545 enrolled
Gastrointestinal

Liver Neoplasms

NCT07309419 2025-12-30

Cocktail-001

Shanghai Zhongshan Hospital

Phase 2/3 Not yet recruiting
222 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡